Article Sidebar

PDF
Date Published: 27/04/2023
Abstract Views: 657
Views PDF: 309
DOI: https://doi.org/10.51298/vmj.v525i2.5150
Issue
Vol. 525 No. 2 (2023)
Section
Các bài báo
How to Cite
Đỗ, H. K. ., & Nguyễn, V. T. . (2023). ASSESSING THE TREATMENT RESULTS OF SECOND-LINE IRINOTECAN MONOTHERAPY IN EXTENSIVE SMALL CELL LUNG CANCER. Vietnam Medical Journal, 525(2). https://doi.org/10.51298/vmj.v525i2.5150

ASSESSING THE TREATMENT RESULTS OF SECOND-LINE IRINOTECAN MONOTHERAPY IN EXTENSIVE SMALL CELL LUNG CANCER

Hùng Kiên Đỗ1,, Văn Tài Nguyễn2
1 K hospital
2 k hospital

Main Article Content

Abstract

Objective: Assessing treatment results of second-line irinotecan chemotherapy in patients with recurrent/metastatic small-cell lung cancer at K Hospital. Patients and method: Retrospective and prospective analysis of 32 recurrent/metastatic small-cell lung cancer patients treated with second-line irinotecan chemotherapy at K Hospital from 01/2018 to 11/2022. Results: Majority of patient were male (78.1%) with age < 60 years old (68.8%). ECOG performance status 0 was observed in 59.4%. Partial response rate was seen in 5 patients (15.6%) and 6 patients of stable disease (18.8%). Disease control rate was 34.4%. Symptoms relief was reported in the majority of patients after chemotherapy. Conclusion: Second-line of irinotecan chemotherapy for the treatment of extensive small cell lung cancer had improved clinical symptoms with disease response rate of 34.4%.

Article Details

Keywords

small-cell lung cancer, extensive stage, second line of irinotecan

References

1. Foster N.R. Qi RINOTECAN. Shi Q. et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 2011; 117: 1262-1271
2. Mascaux, C., Paesmans, M., Berghmans, T. et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000; 30: 23–26
3. Rossi, A., Di Maio, M., Chiodini, P. et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012; 30: 1692–1698
4. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018; 379:2220.
5. Goto K, Ohe RINOTECAN, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2016; 17:1147.
6. SEER Cancer Statistics Review, 1975-2016. SEER. Accessed November 26, 2022. https://seer.cancer.gov/csr/1975_2016/index.html
7. Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist. 2009;14(10):986-994. doi:10.1634/theoncologist.2009-0026
8. Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7(5):866-872. doi:10.1097/JTO.0b013e31824c7f4b
9. Zhao RINOTECAN, Wan B, Zhang T, et al. Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis. Transl Lung Cancer Res. 2019;8(6):829-837. doi: 10.21037/tlcr.2019.10.21
10. Kondo R, Watanabe S, Shoji S, et al. A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer. OCL. 2018; 94(4):223-232. doi:10.1159/000486622